Recombinant Zebrafish ADCY1A

• Cat.No.: ADCY1A-7643Z
• Product Overview: Recombinant Zebrafish ADCY1A full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Zebrafish
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: adcy1a adenylate cyclase 1a [ Danio rerio (zebrafish) ]
• Official Symbol: ADCY1A
• Gene ID: 557026
• mRNA Refseq: NM_001168349
• Protein Refseq: NP_001161821
• UniProt ID: D1MIA2

Q&As

How are ADCY1A-targeted therapies developed and tested?

ADCY1A-targeted therapies are typically developed through a process that involves identifying potential compounds, testing their effects on ADCY1A activity and cAMP signaling in vitro and in animal models, and conducting clinical trials to evaluate their safety and efficacy in humans.

Can targeting ADCY1A be used for cancer treatment?

ADCY1A has been implicated in cancer progression and metastasis through its role in regulating cAMP signaling. Modulating ADCY1A activity may be a potential strategy for inhibiting cancer growth and metastasis, but more research is needed to evaluate the safety and efficacy of this approach.

How long may it take for ADCY1A-based therapies to be available for clinical use?

The timeline for the development of ADCY1A-based therapies depends on various factors, including the complexity of the compounds and the regulatory requirements for conducting clinical trials. Some compounds may require years of preclinical studies before they can enter clinical trials, and the clinical trial process can take several years as well. It may be several years or even decades before ADCY1A-based therapies become available for clinical use.

How can ADCY1A be targeted for medical applications?

ADCY1A can be targeted for medical applications through the development of compounds that modulate its activity or expression. These compounds can potentially increase or decrease cAMP signaling, depending on the specific application.

What challenges need to be addressed in the development of ADCY1A-based therapies?

Challenges in the development of ADCY1A-based therapies include the lack of specificity of some compounds, potential toxicity issues, and the complexity of the cAMP signaling pathway. Moreover, the ethical concerns related to testing experimental drugs in humans, and the regulatory requirements for conducting clinical trials, can pose additional challenges.

Are there any FDA-approved drugs that target ADCY1A?

Currently, there are no FDA-approved drugs that directly target ADCY1A. However, there are several drugs that indirectly affect cAMP signaling, including beta-blockers, which inhibit the activity of beta-adrenergic receptors that activate ADCY1A.

What are the potential benefits of ADCY1A-based therapies?

ADCY1A-based therapies could potentially improve the management of medical conditions by targeting key pathways involved in their pathogenesis. This could lead to better clinical outcomes, enhanced quality of life for affected individuals, and potentially reduce healthcare costs associated with these conditions.

What medical conditions may benefit from targeting ADCY1A?

ADCY1A has been implicated in various medical conditions, including cancer, metabolic disorders, and neurological disorders. Targeting ADCY1A may be a strategy to modulate cAMP signaling and improve the pathogenesis of these diseases.

How does modulating ADCY1A differ from other approaches to treating medical conditions?

Modulating ADCY1A activity offers a targeted approach to regulating cAMP signaling and downstream physiological processes, potentially minimizing off-target effects and toxicity associated with less specific approaches. Moreover, targeting ADCY1A can potentially activate or inhibit cAMP signaling in a cell- or tissue-specific manner, leading to more precise regulation of physiological processes.

Are there any known side effects of targeting ADCY1A?

The potential side effects of targeting ADCY1A depend on the specific compound and the extent of its effects on cAMP signaling. While some compounds may have minimal side effects, others may affect multiple physiological processes and have more significant side effects. More research is needed to fully evaluate the safety and efficacy of ADCY1A-targeted therapies.

Are there any current ADCY1A-based therapies in clinical trials?

There may be ongoing preclinical studies evaluating the effect of various compounds on ADCY1A activity and cAMP signaling. However, as of now, there are no known ADCY1A-based therapies in clinical trials for any disease or medical condition.

What methods are being used to target ADCY1A in drug development?

Different compounds are being developed to modulate ADCY1A activity, including small molecules, peptides, and antibodies. The effects of these compounds on cAMP signaling and downstream physiological processes are evaluated in cell culture studies, animal models, and clinical trials.

What diseases or medical conditions can be treated by targeting ADCY1A?

ADCY1A has been implicated in the pathogenesis of various diseases, including type 2 diabetes, heart failure, and cancer. Targeting ADCY1A may be a potential strategy for treating these conditions, as well as other diseases that involve dysregulation of cAMP signaling.